Paris, France-based Carthera designed SonoCloud to treat a wide range of brain disorders. The device emits ultrasound to temporarily increase the permeability of blood vessels in the brain, improving therapeutic molecule delivery.
After implantation in the skull, SonoCloud activates prior to the injection of a therapeutic agent. Several minutes of low-intensity ultrasound opens the blood-brain barrier (BBB) for six hours, increasing the concentration of therapeutic molecules in the brain.
Get the full story at our sister site, Drug Delivery Business News.